David Yen, MD
Otolaryngology · Bethlehem, PANPI 1033174503
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $961,590 of the $1,393,545 with a category attached, or 69.0%. 36 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 42.1% of the total. Among otolaryngology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,518 payments — averaging $918.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$586K
- Sanofi$521K
- Stryker$159K
- Medtronic$66K
- Neurent Medical Limited$40K
- Oyster Point Pharma, Inc.$8K
- plus $13K from 30 others
Across 147 payments — averaging $4932.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$210K
- Neurent Medical Limited$153K
- Aerin Medical Inc.$121K
- Spirair, Inc.$109K
- GSK$104K
- Arrinex, Inc.$26K
- plus $3K from 1 others
What the payments were for
- Consulting fees$246,72718%
- Speaking & faculty fees$961,59069%
- Travel & lodging$147,43211%
- Food & beverage$36,9803%
- Education$8120%
- Gifts$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 555 | $586,495 |
| Sanofi | 426 | $521,417 |
| Stryker | 146 | $158,630 |
| Medtronic(2 entities) | 115 | $66,018 |
| Neurent Medical Limited | 91 | $40,303 |
| Oyster Point Pharma, Inc. | 1 | $8,050 |
| Aerin Medical Inc. | 33 | $3,258 |
| Genentech USA, Inc. | 1 | $2,125 |
| Intuitive Surgical | 9 | $1,417 |
| Optinose US, Inc. | 34 | $880 |
| Medical Device Business Services, Inc. | 7 | $833 |
| GSK | 26 | $766 |
| Acclarent, Inc | 8 | $579 |
| Spirair, Inc. | 2 | $320 |
| AstraZeneca | 6 | $301 |
| Inspire Medical Systems, Inc. | 3 | $299 |
| Preceptis Medical, Inc. | 4 | $284 |
| Biocryst US Sales Co., LLC | 3 | $186 |
| Phathom Pharmaceuticals, Inc. | 3 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $152 |
| Arrinex, Inc. | 1 | $131 |
| Organogenesis Inc. | 3 | $129 |
| Smith+Nephew | 3 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $112 |
| Intersect ENT, Inc. | 4 | $100 |
| Merck | 6 | $88 |
| Pfizer | 5 | $75 |
| KARL Storz Endoscopy-america | 1 | $52 |
| 3nt Medical | 1 | $50 |
| Hologic Sales And Service, LLC | 3 | $45 |
| Biofire Diagnostics, LLC | 1 | $36 |
| Amgen | 1 | $34 |
| Ionis Pharmaceuticals, Inc. | 1 | $32 |
| Alk-abello, Inc | 2 | $31 |
| Covidien LP | 1 | $14 |
| Atos Medical Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$1,201,900
- ENTELLUS - XPRESS ENT DILATION SYSTEM$142,940
- NEUROMARK Device$37,247
- NEUROMARK Radiofrequency Generator$25,324
- CLARIFIX CRYOTHERAPY DEVICE$12,750
- NEUROMARK Radiofrequency Console$12,654
- PROPEL$10,067
- STRAIGHTSHOT$9,332
- FUSION$8,983
- TYRVAYA$8,050
- NIM Vital$7,361
- ENDO-SCRUB$6,745
- XPRESS ENT DILATION SYSTEM$2,906
- LATERA$2,521
- XOLAIR$2,125
- VIVAER STYLUS$1,630
- RHINAER STYLUS$1,630
- Da Vinci Surgical System$1,260
- NEUROMARK System$731
- SeptAlign$493
How this compares
$1,393,545 in reported general payments places this provider in the 95th percentile of 456 otolaryngology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 16 | $36 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Bethlehem
- Alexander LimjucoBethlehem$15K
- Aaron JaworekBethlehem$7K
- Jacquelyn MichalskiBethlehem$7K
- David BrownBethlehem$7K
- Glenn KayeBethlehem$6K
- Nancy SnydermanPhiladelphia$4.5M
- David KennedyPhiladelphia$603K
- Stella LeePittsburgh$438K
- James PalmerPhiladelphia$331K
- Ryan SooseSeven Fields$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.